Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy

Show simple item record

dc.contributor.author Wong, Stephen N. en_US
dc.contributor.author Chu, Chi-Jen en_US
dc.contributor.author Wai, Chun-Tao en_US
dc.contributor.author Howell, Terese en_US
dc.contributor.author Moore, Charles en_US
dc.contributor.author Fontana, Robert J. en_US
dc.contributor.author Lok, Anna S. -F. en_US
dc.date.accessioned 2007-09-20T18:20:29Z
dc.date.available 2008-04-03T18:52:37Z en_US
dc.date.issued 2007-03 en_US
dc.identifier.citation Wong, Stephen N.; Chu, Chi-Jen; Wai, Chun-Tao; Howell, Terese; Moore, Charles; Fontana, Robert J.; Lok, Anna S.F. (2007). "Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy." Liver Transplantation 13(3): 374-381. <http://hdl.handle.net/2027.42/55976> en_US
dc.identifier.issn 1527-6465 en_US
dc.identifier.issn 1527-6473 en_US
dc.identifier.uri http://hdl.handle.net/2027.42/55976
dc.identifier.uri http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17318855&dopt=citation en_US
dc.description.abstract Hepatitis B virus (HBV) recurrence rates of 0-16% had been reported in patients maintained on nucleoside analogues (NA) after hepatitis B immunoglobulin (HBIG) discontinuation after orthotopic liver transplantation (OLT). However, follow-up in most studies was short. We aimed to determine the long-term risk of HBV recurrence using this strategy. All HBV patients who received ≥7 doses of intravenous HBIG after OLT, with no HBV recurrence while receiving HBIG, and who eventually discontinued HBIG and were maintained on NA, were included. HBV recurrence was defined as HBsAg-positive or HBV DNA ≥5 log copies/mL on 2 consecutive occasions. Twenty-one patients met the inclusion criteria. Immediate post-OLT prophylaxis was combination HBIG and NA in 15 patients, whereas 6 patients received HBIG monotherapy for 62-109 months before NA was added. HBIG was discontinued a median of 26 (range, 0.2-121) months after OLT. Median follow-up post-HBIG discontinuation was 40 (range, 5-51) months. Only 1 patient, who had 12 months of HBIG and was noncompliant to NA therapy, had HBV recurrence, 34 months after HBIG discontinuation. One patient had HBV DNA of 3.3 log copies/mL 47 and 48 months after HBIG discontinuation but remained HBsAg-negative. Lamivudine-resistant mutations were detected in both patients. Probability of HBV recurrence was 0% and 9% at 2 and 4 years after HBIG discontinuation. Three patients had 1-2 episodes of transiently detectable HBV DNA. All were HBV DNA and HBsAg negative on repeated tests over a period of 2-36 months. Maintenance therapy with NA after discontinuation of long-term HBIG therapy is associated with a low risk of HBV recurrence after OLT in compliant HBV patients. Liver Transpl 13:374–381, 2007. © 2007 AASLD. en_US
dc.format.extent 107665 bytes
dc.format.extent 3118 bytes
dc.format.mimetype application/pdf
dc.format.mimetype text/plain
dc.publisher Wiley Subscription Services, Inc., A Wiley Company en_US
dc.subject.other Life and Medical Sciences en_US
dc.subject.other Surgery en_US
dc.title Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy en_US
dc.type Article en_US
dc.rights.robots IndexNoFollow en_US
dc.subject.hlbtoplevel Health Sciences en_US
dc.description.peerreviewed Peer Reviewed en_US
dc.contributor.affiliationum Division of Gastroenterology, University of Michigan, Ann Arbor, MI en_US
dc.contributor.affiliationum Division of Gastroenterology, University of Michigan, Ann Arbor, MI en_US
dc.contributor.affiliationum Division of Gastroenterology, University of Michigan, Ann Arbor, MI en_US
dc.contributor.affiliationum Division of Gastroenterology, University of Michigan, Ann Arbor, MI ; Department of Surgery, University of Michigan, Ann Arbor, MI en_US
dc.contributor.affiliationum Division of Gastroenterology, University of Michigan, Ann Arbor, MI en_US
dc.contributor.affiliationum Division of Gastroenterology, University of Michigan, Ann Arbor, MI en_US
dc.contributor.affiliationum Division of Gastroenterology, University of Michigan, Ann Arbor, MI ; Telephone: 734-615-4628; FAX: 734-936-7392 ; Anna Lok, Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109-0362 en_US
dc.identifier.pmid 17318855 en_US
dc.description.bitstreamurl http://deepblue.lib.umich.edu/bitstream/2027.42/55976/1/21041_ftp.pdf en_US
dc.identifier.doi http://dx.doi.org/10.1002/lt.21041 en_US
dc.identifier.source Liver Transplantation en_US
dc.owningcollname Interdisciplinary and Peer-Reviewed
 Show simple item record

This item appears in the following Collection(s)


Search Deep Blue

Advanced Search

Browse by

My Account

Information

Coming Soon


MLibrary logo